Publication Name	World Journal of Clinical Cases
Manuscript ID	78319
Country	China

Received	2022-06-20 08:31
Peer-Review Started	2022-06-20 08:36
To Make the First Decision
Return for Revision	2022-09-05 02:12
Revised	2022-09-13 14:01
Second Decision	2022-10-18 03:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-10-18 07:52
Articles in Press	2022-10-18 07:52
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-10-27 13:48
Publish the Manuscript Online	2022-11-08 07:44

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Case Control Study
Article Title	Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation
Manuscript Source	Unsolicited Manuscript
All Author List	Sai-Ling Hu, Min Liu and Jun-Yu Zhang
ORCID	Author(s) ORCID Number Sai-Ling Hu http://orcid.org/0000-0002-9535-3516 Min Liu http://orcid.org/0000-0002-8540-5095 Jun-Yu Zhang http://orcid.org/0000-0002-1013-8172
Funding Agency and Grant Number	Funding Agency Grant Number Medical Health Science and Technology Project of Zhejiang Province Health Commission 2020ZH013
Corresponding Author	Jun-Yu Zhang, MM, Chief Doctor, Department of Hematology, Lishui Municipal Central Hospital, No. 289 KuoCang Road, Lishui 323000, Zhejiang Province, China. zhangjunyu815@163.com
Key Words	Dexamethasone; Maintenance treatment; Multiple myeloma; Efficacy; Toxicity
Core Tip	Multiple myeloma (MM) is a plasma cell malignancy. MM treatment includes induction therapy, consolidation therapy, and maintenance therapy. Based on the past clinical activities, we discovered that a part of patients suffered from serious adverse gastrointestinal reactions after oral administration of 40 mg dexamethasone (DXM) once every week. Consequently, we divided DXM 40 mg administered once a day into 20 mg continuously administered over two days, after which we compared the efficacy and toxicity in DXM 40 mg and 20 mg group as maintenance. The two groups have equally efficience as maintenance treatment in standard-risk patients’ non-eligible for transplantation. However, DXM 40 mg once per day per week exhibited a higher incidence rate in adverse gastrointestinal reactions in short-term, but lower non-hematological toxicity in the long-term contained bone lost, abnormal of blood glucose and insomnia. DXM 40 mg once per day every week may be safer and lead to a better quality of life.
Publish Date	2022-11-08 07:44
Citation	Hu SL, Liu M, Zhang JY. Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. World J Clin Cases 2022; 10(32): 11712-11725
URL	https://www.wjgnet.com/2307-8960/full/v10/i32/11712.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i32.11712

Full Article (PDF)	WJCC-10-11712.pdf
Full Article (Word)	WJCC-10-11712.docx
Manuscript File	78319_Auto_Edited-JLW.docx
Answering Reviewers	78319-Answering reviewers.pdf
Audio Core Tip	78319-Audio core tip.mp3
Biostatistics Review Certificate	78319-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	78319-Conflict-of-interest statement.pdf
Copyright License Agreement	78319-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	78319-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	78319-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	78319-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	78319-Language certificate.pdf
Peer-review Report	78319-Peer-review(s).pdf
Scientific Misconduct Check	78319-Bing-Chen YL-2.png
Scientific Editor Work List	78319-Scientific editor work list.pdf